EUVIMEDEUVIMED entdecken
Crossref

Nanobiotechnology for dendritic cell-based cancer immunotherapy

Rongzhang Li, Wenzhe Yi, Xindi Qian, Shuangshuang Hu, Honggang Shen, Dan Yan, Yaping Li

Cell Biomaterials · 2026-05 · 100485

DOI: 10.1016/j.celbio.2026.100485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biomaterials, 2026-05. Verfasst von Rongzhang Li und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 374 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences, Science and Technology Commission of Shanghai Municipality.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Science and Technology Commission of Shanghai Municipality
  • Ministry of Science and Technology of the People's Republic of China
  • National Key Research and Development Program of China

Zitieren

APA

Li, R., Yi, W., Qian, X., Hu, S., Shen, H., Yan, D., & Li, Y. (2026). Nanobiotechnology for dendritic cell-based cancer immunotherapy. Cell Biomaterials, 100485. https://doi.org/10.1016/j.celbio.2026.100485

Vancouver

Li R, Yi W, Qian X, Hu S, Shen H, Yan D, et al. Nanobiotechnology for dendritic cell-based cancer immunotherapy. Cell Biomaterials. 2026:100485. doi:10.1016/j.celbio.2026.100485

BibTeX
@article{Li2026,
  author = {Li, Rongzhang and Yi, Wenzhe and Qian, Xindi and Hu, Shuangshuang and Shen, Honggang and Yan, Dan and Li, Yaping},
  title = {Nanobiotechnology for dendritic cell-based cancer immunotherapy},
  journal = {Cell Biomaterials},
  year = {2026},
  pages = {100485},
  doi = {10.1016/j.celbio.2026.100485}
}
Kostenlos starten →